According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Type 1 diabetes (T1D) is an autoimmune condition where the body cannot produce insulin properly, and this can affect the life ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Taking prednisone can make the liver resistant to insulin, raising blood sugar levels and potentially leading to steroid-induced diabetes. Steroids may also worsen existing diabetes symptoms.